Oncopeptides: Funding, Investors & Team (Sep 2026)
Oncopeptides is a clinical stage company backed by HealthCap and Industrifonden that has raised approximately 16.5 MEUR in Early Stage and Series A financing to 2015. Oncopeptides lead compound, named melflufen, is a peptidase potentiated therapy within oncology. Melflufen is a very potent anti-angiogenetic compound, triggers rapid, robust, and irreversible DNA damage and exerts it cytotoxicity through alkylation of DNA. Melflufen is currently undergoing Phase 2 efficacy studies in patients with relapsed and relapsed-refractory multiple myeloma. The peptidase targeting causes melflufen and its metabolites to accumulate in the diseased cells. This results in targeted delivery of the active moieties to the cancer cells, and thereby better treatment of the disease.
Oncopeptides has raised $470k across 1 funding round on record, the most recent a Grant of $470k announced in Sep 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Oncopeptides Company Profile and Key Stats
Latest funding round on record: Sep 2022.
Oncopeptides Funding Rounds
Oncopeptides Founders and Leadership Team
Contact details for the Oncopeptides team: 1 of 1 has an email address on file.
Start 14-day free trial →Oncopeptides Funding Compared to Other Biotechnology Startups
Oncopeptides' latest round of $470k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Oncopeptides in Biotechnology and Stockholm
Companies Similar to Oncopeptides
Pixelgen Technologies, established in Sweden in 2020, focuses on the advancement of biomedical research and…
Oblique Therapeutics is developing a new type of antibody-based medication for chronic pain and metastatic…
Emulsi Biotech is a biotechnology company that develops lipid technology to deliver biologic drugs orally.
Our vision is to develop and bring to the market safe and effective treatments for women specific diseases…
OncoZenge is a Swedish pharmaceutical company. It develops better products for the supportive care of cancer…
Elicera Therapeutics is a clinical stage immuno-oncology company developing cell and gene therapies for…
Alligator Bioscience is an innovative research based biotech company focused on developing novel drugs for…
Moleculent is dedicated to creating tech-based products that utilize fresh knowledge about the molecular…
Bio-Works was established in 2006 and specializes in creating, producing, and distributing cutting-edge…
Verigraft AB is a biotech company that creates personalized tissue-engineered transplants for use in…
Lipum aims to eliminate or alleviate painful symptoms for millions of patients suffering from chronic…
ArgusEye is a biotech firm that offers sensor solutions for instant identification of biological systems and…
Oncopeptides Funding FAQs
What does Oncopeptides do?
Oncopeptides is a clinical stage company backed by HealthCap and Industrifonden that has raised approximately 16.5 MEUR in Early Stage and Series A financing to 2015. Oncopeptides lead compound, named melflufen, is a peptidase potentiated therapy within oncology. Melflufen is a very potent anti-angiogenetic compound, triggers rapid, robust, and irreversible DNA damage and exerts it cytotoxicity through alkylation of DNA. Melflufen is currently undergoing Phase 2 efficacy studies in patients with relapsed and relapsed-refractory multiple myeloma. The peptidase targeting causes melflufen and its metabolites to accumulate in the diseased cells. This results in targeted delivery of the active moieties to the cancer cells, and thereby better treatment of the disease.
How much funding has Oncopeptides raised?
Oncopeptides has raised $470k across 1 round on record. The most recent is a Grant of $470k announced in Sep 2022.
When did Oncopeptides last raise funding?
Oncopeptides' most recent funding round on record is a Grant of $470k, announced in Sep 2022.
Who is the CEO of Oncopeptides?
Anders Martin is listed as CEO at Oncopeptides.
Where is Oncopeptides headquartered?
Oncopeptides is based in Stockholm, Stockholms Lan, Sweden.
How many employees does Oncopeptides have?
Oncopeptides is in the 251-500 employee band.
How does Oncopeptides' funding compare to other Biotechnology startups?
Oncopeptides' latest round of $470k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Oncopeptides Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Oncopeptides is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.